Kodiak Sciences：DAYBREAK研究需交出超越及格的答卷（纳斯达克：KOD）
· seekingalpha.com
Kodiak预计本月将公布Zenkuda和KSI-501在湿性黄斑变性中的3期DAYBREAK研究结果。阅读为何KOD股票应持有。
Kodiak Sciences ( KOD ) has a credible chance to bring a longer-lasting treatment to the retinal drug market. The harder question is whether its coming clinical...